REG - Surgical Innovations - Update on contingency planning for no-deal Brexit

Surgical InnovationsAnnouncement

20/02/2019 07:06

RNS Number : 5357Q
Surgical Innovations Group PLC
20 February 2019
 


Surgical Innovations Group plc
("Surgical Innovations" or "the Company")
 
Update on contingency planning for no-deal Brexit
 
Surgical Innovations (AIM: SUN), the designer and manufacturer of innovative technology for minimally invasive surgery, provides an update on contingency planning for the possibility of the U.K. leaving the EU without an appropriate Withdrawal Agreement.
 
On 15 February 2019, BSI Netherlands confirmed the successful reassignment of all of the Company's product certification from BSI Notified Body 0086 (U.K.) to the Netherlands Notified Body 2797.
 
Nigel Rogers, Executive Chairman of SI Group, stated: "Amidst speculation in the weekend press of possible disruption to the approvals status of medical devices across the EU following a no-deal Brexit, it is reassuring that we have taken this important precaution. Our first priority is to protect the integrity of our regulatory approvals for the EU market, and this will serve to reassure our distribution partners and end users of continuity in coming months."
 
For further information contact:
 



Surgical Innovations Group Plc


www.sigroupplc.com




Nigel Rogers, Executive Chairman


Tel: +44 (0)113 230 7597




Melanie Ross, COO and CFO


















Walbrook PR (Financial PR & Investor Relations)


Tel: +44 (0)20 7933 8780 or si@walbrookpr.com




Paul McManus


Mob: +44 (0)7980 541 893




Lianne Cawthorne


Mob: +44 (0)7584 391 303














N+1 Singer (Nominated Adviser and Broker)


+44 (0)20 7496 3000




Richard Lindley








Rachel Hayes







 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDEAPANFSENEFF